ArticleClinical transplantation2026
Outcomes of Kidney Transplants From Donors With Stage 3 Acute Kidney Injury Requiring Dialysis: A National Cohort Study.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes of Kidney Transplants From Donors With Stage 3 Acute Kidney Injury Requiring Dialysis: A National Cohort Study.Clinical transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWhether severe donor acute kidney injury (AKI) requiring dialysis affects posttransplant outcomes remains debated and may influence center-level acceptance decisions.
methodsThis retrospective cohort study of United States deceased-donor kidney transplants (2015-2020) used OPTN data with follow-up through September 2024. Donor AKI was staged by KDIGO 2012 criteria, and dialysis was identified using a validated rule-based natural language processing (NLP) algorithm applied to DonorNet records. The primary outcome was all-cause graft failure (ACGF). Secondary outcomes included delayed graft function (DGF), 1-year estimated glomerular filtration rate (eGFR), and a composite tolerability outcome within 6 months defined as DGF, eGFR <30 mL/min/1.73 m
resultsOf 74 939 transplants, 24.6% were from AKI donors (Stage 2 7.8%, Stage 3 without dialysis 5.8%, Stage 3 with dialysis 2.1%). DGF increased with AKI severity (Stage 3 with dialysis 54.5% vs Stage 2 38.1%), but adjusted ACGF risk was similar across groups. Donor KDPI and recipient EPTS were stronger predictors of graft failure than AKI stage. Exploratory tolerability analyses showed that early adverse outcomes were driven primarily by recipient age, BMI, dialysis duration, and organ quality, not by donor AKI severity or dialysis.
conclusionsAmong transplanted kidneys, Stage 3 AKI requiring donor dialysis was associated with higher early DGF but similar adjusted graft survival compared with Stage 2 AKI after accounting for organ quality and recipient risk. These findings reflect outcomes among AKI-affected kidneys accepted for transplantation and should not be generalized to declined or discarded kidneys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.